CR7929A - Proceso para producir una preparacion recubierta - Google Patents

Proceso para producir una preparacion recubierta

Info

Publication number
CR7929A
CR7929A CR7929A CR7929A CR7929A CR 7929 A CR7929 A CR 7929A CR 7929 A CR7929 A CR 7929A CR 7929 A CR7929 A CR 7929A CR 7929 A CR7929 A CR 7929A
Authority
CR
Costa Rica
Prior art keywords
produce
preparation
covered
covered preparation
pioglitazone hydrochloride
Prior art date
Application number
CR7929A
Other languages
English (en)
Inventor
Ohkouchi Kazuhiro
Koike Masahiko
Koyama Hiroyoshi
Hamaguchi Naoru
Original Assignee
Takeda Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32830627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Ltd filed Critical Takeda Pharmaceutical Ltd
Publication of CR7929A publication Critical patent/CR7929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion esta dirigida a proporcionar un proceso para la produccion de una preparacion recubierta con clorhidrato de pioglitazona que es util como un remedio para la diabetes, etc., y tienen excelentes caracteristicas de preparacion tales como la propiedad de disolucion del clorhidrato de pioglitazona.
CR7929A 2003-01-29 2005-08-01 Proceso para producir una preparacion recubierta CR7929A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003020925 2003-01-29
JP2003276894 2003-07-18
JP2004001128 2004-01-06

Publications (1)

Publication Number Publication Date
CR7929A true CR7929A (es) 2005-11-28

Family

ID=32830627

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7929A CR7929A (es) 2003-01-29 2005-08-01 Proceso para producir una preparacion recubierta

Country Status (14)

Country Link
US (1) US7976853B2 (es)
EP (1) EP1588708A4 (es)
KR (1) KR101114808B1 (es)
AU (1) AU2004208606B2 (es)
BR (1) BRPI0407074A (es)
CA (1) CA2514539C (es)
CR (1) CR7929A (es)
IL (1) IL169870A (es)
MA (1) MA27624A1 (es)
MX (1) MXPA05007883A (es)
NO (1) NO20053965L (es)
NZ (1) NZ541749A (es)
PL (1) PL377403A1 (es)
WO (1) WO2004067001A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
AR058605A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
EA016728B1 (ru) * 2006-08-10 2012-07-30 Такеда Фармасьютикал Компани Лимитед Фармацевтическая композиция
TWI453041B (zh) * 2007-02-01 2014-09-21 Takeda Pharmaceutical 固體型製劑
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
CA2912043C (en) * 2013-06-17 2017-08-15 Nippon Soda Co., Ltd. Coating agent comprising hydroxyalkyl cellulose
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
RU2690677C1 (ru) * 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью
CN112461947B (zh) * 2020-10-27 2022-06-28 山东省药学科学院 一种盐酸吡格列酮片溶出曲线的测定方法
CN120392688B (zh) * 2025-07-02 2025-09-16 浙江大学 一种盐酸吡格列酮和二甲双胍复方片剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5179716A (en) 1974-12-28 1976-07-12 Shinetsu Chemical Co Kokeiiyakuseizaino seizohoho
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
NZ274346A (en) 1993-09-15 1997-06-24 Sankyo Co Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
KR20060105005A (ko) 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
WO2001058491A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Drug comprising combination
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
JP2001342185A (ja) * 2000-06-02 2001-12-11 Nichiko Pharmaceutical Co Ltd フィルムコーティングされた塩酸ラニチジン錠剤
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
KR20030076634A (ko) * 2001-01-30 2003-09-26 데이진 가부시키가이샤 의약 조성물
AU2001273289B2 (en) 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
US20030187074A1 (en) 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1552832A1 (en) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003272504A1 (en) 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004069229A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof

Also Published As

Publication number Publication date
KR101114808B1 (ko) 2012-02-15
US20060141128A1 (en) 2006-06-29
EP1588708A4 (en) 2006-03-01
PL377403A1 (pl) 2006-02-06
MA27624A1 (fr) 2005-11-01
EP1588708A1 (en) 2005-10-26
KR20050096958A (ko) 2005-10-06
CA2514539C (en) 2012-03-06
WO2004067001A1 (ja) 2004-08-12
AU2004208606A1 (en) 2004-08-12
NZ541749A (en) 2009-06-26
US7976853B2 (en) 2011-07-12
BRPI0407074A (pt) 2006-01-24
IL169870A (en) 2012-07-31
MXPA05007883A (es) 2005-09-21
NO20053965L (no) 2005-08-25
CA2514539A1 (en) 2004-08-12
AU2004208606B2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
CR7929A (es) Proceso para producir una preparacion recubierta
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
CR10992A (es) Preparacion solida que comprende alogliptina y pioglitazona
PE20150340A1 (es) Formas de dosificacion farmaceutica
BRPI0906335A2 (pt) Substrato compressível, calçado e artigo de manufatura
ATE534378T1 (de) Titrierung von tapentadol
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
ECSP10010295A (es) Formulacion de anticuerpo
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
TWD138600S1 (zh) 耳環
MX2007015424A (es) Formulaciones ungueales topicas.
BRPI0606504A2 (pt) pirazolo piridinas substituìdas, composições que as contêm, processo de fabricação e utilização
SMT201200014B (it) Nalmefene cloridrato diidrato.
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
BRPI0818970A2 (pt) "composição, processo de fabricação de uma composição, artigo e mistura"
BRPI0812146A2 (pt) Processo, mistura, utilização da mistura, borracha sintética
BRPI0717897A2 (pt) Processo para produção de ácido acrílico, aparelho para produção de ácido acrílico e composição para produção de ácido acrílico
BRPI0916108A2 (pt) "composição, processo de produção de uma composição e artigo"
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica